轮椅

Search documents
广东65周岁及以上户籍老年人口占比12.46%
Zhong Guo Xin Wen Wang· 2025-10-10 12:28
老年人积极参加银龄集市上各项摊位活动。广州市民政局 供图 制脸谱,感觉特别有意义。"活动现场还设有义诊、义剪、义修等便民服务点位,受到市民欢迎。 广东65周岁及以上户籍老年人口占比12.46% 中新网广州10月10日电 (记者 蔡敏婕)2025年广东省暨广州市"敬老月"活动启动仪式10日在广州举办。 广东省民政厅党组成员、副厅长熊松表示,广东是老年人口大省,预计到2030年,广东将进入中度老龄 化社会。 截至2024年底,广东全省60周岁及以上户籍老年人口1789.26万人,占比17.46%;全省65周岁及以上户 籍老年人口1277.21万人,占比12.46%。 今年10月是第16个全国"敬老月",结合广东实际,广东省老龄办动员号召全省各地各有关部门在"敬老 月"期间,组织开展人口老龄化国情教育,走访慰问、关爱帮扶困难老年人,普及健康知识、提升老年 群体健康素养,推介养老服务、搭建供需交流保障平台,开展丰富多彩的老年文化活动,实施法治护 航、保障老年人合法权益6项活动。 截至2024年底,广州全市60岁及以上户籍老年人口212.92万人,占户籍总人口19.81%。广州老龄化程度 持续加深,老年群体在生活照料、 ...
网售医疗器械新规落地 守护公众购械“云端”安全
Zhong Guo Xin Wen Wang· 2025-10-02 01:11
Group 1 - The core viewpoint of the articles highlights the implementation of the "Medical Device Online Sales Quality Management Specification" on October 1, which aims to establish clearer safety standards for the rapidly growing online medical device sales sector [1] - The number of companies engaged in online sales of medical devices in China has surged from 8,717 in 2018 to over 360,000, while the number of third-party platform companies has increased from 77 to over 800 [1] - The new specification consists of four chapters and 50 articles, providing specific guidance on common industry issues, helping companies fulfill their responsibilities, and promoting healthy market development [1] Group 2 - Zhejiang Province previously introduced the "Compliance Guidelines for Online Sales of Medical Devices (First Edition)," which includes 29 specific provisions to serve as a practical "operating manual" for companies [2] - The guidelines establish five basic principles: legal compliance, prioritizing quality and safety, ensuring accurate information, maintaining risk control throughout the process, and fully protecting consumer rights [2] - The Zhejiang Provincial Drug Administration has issued reminders for consumers to check the qualifications of sellers and products, choose legitimate platforms, and retain transaction receipts when purchasing medical devices online [2]
医疗辅助技术(AT)行业“十五五”市场战略研究及投资建议可行性评估预测报告(2025版)
Sou Hu Cai Jing· 2025-09-29 02:16
报告发布方:中金企信国际咨询 项目可行性报告&商业计划书专业权威编制服务机构(符合发改委印发项目可行性研究报告编制要求)-中金企信国际咨询:集13年项目编制服务经验为各 类项目立项、投融资、商业合作、贷款、批地、并购&合作、投资决策、产业规划、境外投资、战略规划、风险评估等提供项目可行性报告&商业计划书编 制、设计、规划、咨询等一站式解决方案。助力项目实施落地、提升项目单位申报项目的通过效率。 医疗辅助技术(AT)是指"为人们维持或改善功能从而促进福祉而开发的辅助产品以及相关系统和服务"。 它允许残疾人、老年人和其他在社会参与方面受 到限制的人通过参与教育、工作和社会活动过上独立、健康和富有成效的生活。 AT 减轻了护理人员的负担以及对正规健康和支持服务的需求。 医疗辅助技术能够促进包容和参与,特别是残疾人、老龄化人口和非传染性疾病患者。 辅助产品的主要目的是维持或改善个人的功能和独立性,从而促进 他们的福祉。 它们使人们能够过上健康、富有成效、独立和有尊严的生活,并参与教育、劳动力市场和公民生活。 辅助产品维持或改善个人的功能和独立性,从而促进他们的福祉。 辅助设备和技术的示例包括轮椅、假肢、助听器、视觉辅 ...
White House launches investigations that could lead to tariffs on machinery, medical devices
Youtube· 2025-09-25 11:09
Group 1 - The Trump administration is initiating national security investigations into imports of robotics, industrial machinery, and medical devices, which may lead to future tariffs on these products [1] - In the medical sector, the products under scrutiny include prescription drugs, syringes, and imported medical equipment such as wheelchairs, pacemakers, and insulin pumps [1] - The Commerce Department is soliciting feedback from affected companies to assess whether domestic production can satisfy US demand [1] Group 2 - There is a growing concern about potential shortages in critical medical supplies, emphasizing the need for increased manufacturing within the United States [2]
背背佳不是“万能药”!可孚医疗上半年业绩双降,2024年分红金额超净利润
Sou Hu Cai Jing· 2025-09-22 11:17
Core Viewpoint - The article discusses the challenges and opportunities faced by Kefu Medical, particularly in relation to its acquisition of the brand "Beibeijia" and its upcoming plans for a Hong Kong IPO amid declining revenues and profits [2][3][4]. Group 1: Company Overview - Kefu Medical acquired the brand "Beibeijia" in 2022 for 177 million yuan, reviving a once-popular posture correction product that had faced significant challenges in the past [2][4]. - The company has a diverse product portfolio, including home medical devices, rehabilitation aids, and health monitoring products, with "Beibeijia" being a notable part of its offerings [5][12]. - Kefu Medical ranks second among home medical device companies in China, with a market share of nearly 30% in the posture correction segment [5]. Group 2: Financial Performance - In the first half of 2025, Kefu Medical reported revenues of approximately 1.5 billion yuan, a decline of 4% year-on-year, and a net profit of about 170 million yuan, down 9.5% [3][9]. - The company's revenue growth has been hindered by a significant reliance on a few major clients, with the top five clients contributing 36.7% of revenue in the first half of 2025 [9][10]. - The overall revenue has increased from about 2.4 billion yuan in 2020 to an estimated 3 billion yuan in 2024, but net profit has decreased from 424 million yuan in 2020 to an estimated 312 million yuan in 2024 [7][9]. Group 3: Market Challenges - "Beibeijia" has faced criticism regarding its effectiveness, with many consumers expressing dissatisfaction on social media and complaint platforms, leading to a divided market perception [10][12]. - The product is classified as a consumer-grade item rather than a medical device, which has led to consumer confusion regarding its intended use and effectiveness [12][15]. - Kefu Medical's marketing efforts have included significant advertising expenditures, which increased by 51% in 2024, but these have not translated into sustained revenue growth [10][18]. Group 4: Strategic Moves - Kefu Medical is pursuing a Hong Kong IPO to address funding needs for overseas expansion and ongoing acquisitions, as its previous fundraising efforts from the A-share market have been largely exhausted [24]. - The company has engaged in multiple acquisitions to expand its product offerings and market presence, including recent purchases of medical product companies [18][20]. - The firm has maintained a consistent dividend policy, distributing a total of 1.235 billion yuan in dividends since its IPO, even as it faces financial pressures [22][23].
“背背佳”要带母公司勇闯港股
Sou Hu Cai Jing· 2025-09-15 14:23
本文自南都·湾财社 采写 | 南都·湾财社记者 陈盈珊 "背背佳"这个陪伴无数人青春的矫姿品牌,正带着母公司冲刺资本市场的新目标重回大众视野。 近日,可孚医疗科技股份有限公司(下称"可孚医疗")正式向港交所主板递交上市申请,启动A+H双重上市进程。作为国内家用医疗器械领域的"隐形冠 军",一年赚三亿、三年半营收破百亿的可孚医疗,此次瞄准境外资本市场究竟手握怎样的业绩底牌?光环之下又暗藏哪些挑战? 从背背佳到医疗巨头 可孚医疗的二十年逆袭路 翻开可孚医疗的招股书,业绩曲线呈现出"震荡中优化"的鲜明特征。2022-2024年及2025年上半年,公司营收分别为29.77亿元、28.54亿元、29.83亿元、 14.96亿元——2023年因渠道扩张投入加大出现4.14%的阶段性下滑,2024年迅速回升4.53%,重回增长轨道;2025年上半年受行业季节性因素影响,营收 微降4.03%。 | | | 截至12月31日止年度 | | 截至6月30日止六個月 | | | --- | --- | --- | --- | --- | --- | | | 2022年 | 2023年 | 2024年 | 2024年 | 2025年 ...
山东政采网上商城“助残馆”启用,助力残疾人辅具高效便捷采购
Qi Lu Wan Bao· 2025-09-12 10:53
通讯员 于思宁 三级联动采购 提升资源配置效率 "助残馆"充分发挥了山东省政府采购网上商城"全省一张网"的优势,推动省市县三级联动采购。上级部门可以实时查看下级部门的采购情况,科学指导本区 域内助残器具的购置和适配安装工作。这种聚合全省采购需求的模式,不仅提高了资源配置效率,还为各级残联单位提供了更加便捷、高效的采购渠道。 提升政府采购效能 持续优化服务 自"助残馆"上线以来,已有效拓展全省残疾人辅助器具的购买渠道,加强了供需对接,促进了市场信息的公开透明。下一步,山东省政府采购网上商城将继 续发挥平台示范引领作用,进一步落实助残政策功能,不断完善"助残馆"建设,为残疾人群体提供更加优质、便捷的服务。 多元化产品专区 满足多样化需求 "助残馆"根据残疾人辅助器具的不同功能和使用场景,设立了四大专区:沟通和信息辅助器具、个人移动辅助器具、个人生活自理和防护辅助器具、家庭无 障碍改造设施设备。首批上架的产品涵盖了助视器、助听器、轮椅、手杖等15类常用辅助器具,共计207款产品。这些产品严格遵循基本技术参数要求,并 设定最高控制单价,确保价格透明合理。同时,辅助器具的适配服务成为供应商入驻的必备条件,进一步保障了残 ...
英科医疗手套产能870亿只全球领先 自主研发及设计生产线良品率99%
Chang Jiang Shang Bao· 2025-09-07 23:24
Core Viewpoint - The company, Yingke Medical, is continuing its share repurchase plan, adjusting the maximum repurchase price from 26.51 CNY to 41.88 CNY per share due to a significant increase in its stock price [2][11]. Financial Performance - In the first half of 2025, Yingke Medical achieved a revenue of 49.13 billion CNY, representing an 8.90% year-on-year growth, and a net profit attributable to shareholders of 7.10 billion CNY, which is a 21.02% increase compared to the previous year [3][4]. - The company reported a strong recovery in 2024, with a revenue of 95.23 billion CNY, up 37.65%, and a net profit of 14.65 billion CNY, up 282.63% [6]. Market Position and Strategy - Yingke Medical is a comprehensive medical care product supplier based in China, focusing on personal protective equipment, rehabilitation care, and other medical products, with a significant emphasis on disposable gloves [8][9]. - The company has rapidly diversified its market presence, particularly in non-American regions, achieving a 45% year-on-year increase in sales revenue from overseas non-American markets in the first half of 2025 [7][11]. Production Capacity and Innovation - The annual production capacity for disposable non-latex gloves has reached 87 billion units, positioning the company as a global leader in this sector [9]. - The company invested 2.04 billion CNY in research and development in the first half of 2025, maintaining a product quality rate of over 99% for its glove products [3][10]. Stock Performance and Confidence - Since July, Yingke Medical's stock price has increased by 46.73%, with a maximum increase of 72.52%, prompting the company to raise its share repurchase price to ensure the smooth execution of its repurchase plan [11].
英科医疗推进市场多元化布局 上半年净利润同比增长21.02%
Zheng Quan Ri Bao Wang· 2025-08-28 13:44
Core Viewpoint - In the first half of 2025, the company Inco Medical achieved significant revenue growth despite challenges from international situations and tariffs, with a revenue of 4.913 billion yuan, up 8.9% year-on-year, and a net profit of 710 million yuan, up 21.02% year-on-year [1] Group 1: Industry Overview - The global disposable glove industry has undergone significant changes, with Malaysia dominating the supply before 2019, followed by accelerated production expansion by Chinese companies from 2020 to 2021, leading to a shift in competitive dynamics [1] - The industry faced severe competition and price drops to historical lows from 2022 to 2023 due to supply-demand imbalances, but signs of recovery and improved capacity utilization were noted in 2024 [1] Group 2: Company Performance - In the first half of 2025, the company maintained full production and sales while significantly increasing its development efforts in non-U.S. markets, resulting in a 45% year-on-year increase in overseas non-U.S. market sales and a 35% increase in domestic market sales [1] - The company has established a leading global manufacturing capability with an annual production capacity of 87 billion gloves, including 56 billion nitrile gloves and 31 billion PVC gloves, supported by advanced automated production lines and intelligent control systems [2] Group 3: Future Initiatives - The company is steadily advancing the construction of overseas production bases, enhancing its global supply chain layout to support business globalization [2] - In terms of green development, the company initiated a wind power project in Anhui in 2024, aiming for completion and operation in 2025, which will increase the share of clean energy in its overall energy structure [2] - The company plans to integrate green energy with medical production to promote sustainable development in the industry [2]
英科医疗:2025年上半年归属股东净利润7.1亿元,同比增长21.02%丨财面儿
Cai Jing Wang· 2025-08-28 12:34
Core Insights - The company reported a revenue of 4.913 billion yuan for the first half of 2025, representing a year-on-year growth of 8.9% [1] - The net profit attributable to shareholders reached 710 million yuan, showing a year-on-year increase of 21.02% [1] Company Overview - The company is a comprehensive medical care product supplier based in China, with main business segments including personal protection, rehabilitation care, and other products [1] - Key products include disposable gloves, wheelchairs, hot and cold packs, and electrode pads, which are widely used in medical institutions, elderly care facilities, daily consumer use, and other related industries [1] Rehabilitation Care Products - The company's rehabilitation care products fall under the category of assistive walking devices, which include electric wheelchairs, manual wheelchairs, walkers, walking aids, canes, and medical bedside tables [1] - These products serve as mobility aids for individuals with physical disabilities, the elderly, and those with limited mobility, facilitating walking, hospital care, and daily assistance for disabled individuals [1]